Pharmacoeconomic analysis of recombinant factor Vlla versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 23-31

  Joshi, Ashish V ^a   Stephens, Jennifer M ^b   Munro, Vicki ^c   Mathew, Prasad ^d   Botteman, Marc F ^b  

^a NOVO NORDISK INC   (United States)

^b PHARMERIT INTERNATIONAL   (United States)

^c Novo Nordisk Ltd   (United Kingdom)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Activated prothrombin complex concentrate; APCC; Economic model; FEIBA; Hemophilia with inhibitors; Monte Carlo simulation; NovoSeven; Probabilistic sensitivity analysis; rFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BODY WEIGHT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEMOPHILIA; HOME CARE; HOSPITAL COST; HUMAN; MONTE CARLO METHOD; SENSITIVITY ANALYSIS; UNITED STATES; UNIVARIATE ANALYSIS;

BLOOD COAGULATION FACTORS; DRUG COSTS; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; UNITED STATES;

EID: 30844444574     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80224     Document Type: Conference Paper

References (26)

1. Lusher JM. Recombinant factor VIIa (NovoSeven®) in the treatment of internal bleeding in patients with Factor VIII and IX inhibitors. Haemostasis 1996;26(Suppl 1):124-30
2. FEIBA® VH Anti-Inhibitor Coagulant Complex, vapor heated, product information. Revised May 2004. Baxter Healthcare Corporation, Westlake Village, CA. Available at http://www. baxter.com/products/biopharmaceuticals/hemophilia/ sub/feiba_vhhtml [last accessed 28 June 2005]
3. NovoSeven® product information. Novo Nordisk Inc, Princeton, New Jersey. Available at http://www.us.novoseven.com/content/ us_vers/us_novoseven. asp [last accessed 28 June 2005]
4. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-7
5. Monroe DM, Hoffman M, Oliver JA, et al. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S15-S20
6. Brackmann HH, Effenberger E, Hess L, et al. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000;11(Suppl 1):S39-S44
7. Lacey L. Economic impact of treating inhibitor patients. Pathophysiol Haemost Thromb 2002;32(Suppl 1):29-32
8. Aldecort L (meeting chair). Meeting report. Economic aspects of haemophilia care. Haemophilia 1999;5:216-9
9. Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999;5:397-401
10. Knight C, Paisley S, Wight J, et al. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003;9:521-40
11. Laurian Y, Goudemand J, Negrier C, et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII and factor IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998;9 (Suppl 1):S155-S156
12. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80(6):912-8
13. Ingerslev J, Thykjaer H, Schiebel E. Approaches towards successful home treatments in patients with inhibitors. Eur J Haematol Suppl 1998;63:11-4
14. Hilgartner M, Aledort L, Andes A, et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients [FEIBA Study Group]. Transfusion 1990;30:626-30
15. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997;77:1113-9
16. Blettner M, Sauerbrei W, Schlehofer B, et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28:1-9
17. National Center for Health Statistics. Growth chart 2 to 20 years: boys. Stature-for-age and weight-for-age percentiles. Centers for Disease Control and Prevention, May 30, 2000. Available at http://www.cdc.gov/growthcharts [last accessed 14 July 2005]
18. Anon. Drug topics redbook updates. Montvale, New Jersey: Thomson Medical Economics, Inc.; August, 2005
19. Rahim MT, Milbrandt EB, Dremsizov TT, et al. Pricing critical care: an updated Russell equation. Presented at the Society of Critical Care Medicine, 33rd Critical Care Congress, Orlando, FL - February 20-25, 2004
20. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500
21. Ekert H, Brewin T, Boey W, et al. Cost-utility of recombinant factor VIIa (NovoSeven®) in six children with long-standing inhibitors to factors VIII and IX. Haemophilia 2001;7:279-85
22. Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2002;5:119-33
23. Dundar S, Zulfikar B, Kavakli K, et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005;8:45-54
24. Berger A, Edelsberg J, Neufeld E, et al. Cost-effectiveness of FEIBA VH vs. rFVIIa as initial therapy for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors. Poster presentation at the Hemophilia 2004 World Congress, October 17-21, 2004, Bangkok, Thailand [abstract No. 114E]
25. Putnam KG, Bohn RL, Ewenstein BM, et al. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-litre inhibitors. Haemophilia 2005;11:261-9
26. Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J Manag Care Pharm 2005;11(Suppl 4):S7-S10